MetaCap

MBX Biosciences (MBX) vs Perrigo (PRGO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MBX Biosciences (MBX) has outperformed Perrigo (PRGO) over the past year, gaining 83.0% versus a gain of 26.1%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.21 billion), about 1.1 times the size. Perrigo pays a dividend yielding 7.28%, while MBX Biosciences does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBX+82.98%PRGO+26.11%
+170%+67%-36%
Nov 21, 20251 yearNov 20, 2026
MBX+109.51%PRGO-42.56%
+203%+58%-88%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBX versus PRGO key metrics
MetricMBXPRGO
Share price$49.55$15.94
Market cap$2.46B$2.21B
1-day change-7.23%-0.62%
YTD return+57.10%+14.51%
1-year return+82.98%+26.11%
5-year return—-57.81%
Forward P/E—6.94
EPS (TTM)$-3.03$-12.47
Dividend yield0.00%7.28%
Annual dividend$0.00$1.16
Revenue (latest FY)—$4.25B
Revenue growth (YoY)—-2.75%
Net income (latest FY)$-87.00M$-1.43B
Gross margin—35.14%
Operating margin—-26.39%
Net margin—-33.51%
52-week high$72.64$17.07
52-week low$26.14$9.23
Distance from 52-week high-31.79%-6.62%
Analyst consensusstrong_buybuy
Avg. price target upside+91.91%+12.92%
Average volume532.80K2.54M
Shares outstanding49.66M138.80M
Employees638,100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MBX has outperformed PRGO by 56.9 percentage points over the past year.
  • Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).

About MBX Biosciences

MBX stock →

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Perrigo

PRGO stock →

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees

MBX vs PRGO FAQ

Which is bigger, MBX Biosciences or Perrigo?

MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.21B for Perrigo (PRGO).

Which stock has performed better over the past year, MBX or PRGO?

MBX returned +82.98% over the past 12 months, compared with +26.11% for PRGO (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, MBX Biosciences or Perrigo?

Perrigo pays a dividend yielding 7.28%, while MBX Biosciences does not currently pay a regular dividend.

Are MBX Biosciences and Perrigo in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons